干扰素和穿孔素在非小细胞肺癌中杀瘤效应探讨

Effect of interferon-γ and perforin in killing cancer cell of non-small cell lung cancer

目的探讨干扰素和穿孔素在非小细胞肺癌中杀瘤效应。方法将具有完整分期(Ⅰ、Ⅱ、Ⅲ、Ⅳ期)的非小细胞肺癌患者,随机抽取35例,分析其在Ⅰ、Ⅱ、Ⅲ、Ⅳ期中白细胞抗原分化群8阳性T淋巴细胞(CD8+T细胞)及其分泌细胞因子干扰素-γ和穿孔素,并进行Spearm an分析。结果Ⅰ、Ⅱ、Ⅲ、Ⅳ期非小细胞肺癌中CD8+T细胞占淋巴细胞百分比分别为(54.14±10.80)%、(43.21±8.57)%、(32.17±7.27)%,(24.52±5.61)%;CD8+T细胞表达干扰素-γ占CD8+T细胞百分比分别为(69.84±12.34)%、(56.27±10.57)%、(45.15±8.54)%、(38.58±6.89)%;表达穿孔素占CD8+T细胞百分比分别为(66.24±13.57)%、(55.28±11.73)%、(43.87±8.84)%、(36.21±5.85)%;各时期非小细胞肺癌两两相比,CD8+T细胞及其分泌细胞因子干扰素-γ和穿孔素的百分比差异均有统计学意义(均P<0.01);经Spearm an相关分析发现,非小细胞肺癌的分期与CD8+T细胞及其表达的干扰素-γ和穿孔素的百分比呈负相关,秩相关系数分别为-0.824、-0.764、-0.746(均P<0.01)。结论随着疾病的进展,非小细胞肺癌患者CD8+T细胞及其分泌细胞因子干扰素-γ和穿孔素均下降,具有杀伤肿瘤效应的免疫功能减弱。

Objective To investigate the effect of killing cancer cell in different phrase of non-small cell lung cancer （NSCLC）. Methods Thirty-five patients with NSCLC in Ⅰ , Ⅱ, Ⅲ and Ⅳ stages were randomized to acquire when the illness developed. Then CD8^＋T cell, interferon-γ,perforin of each group were measured by flow cytometry. Meanwhile,the Spearman correlation was carried out between the four stages and the CD8^＋ T cell, interferon-γ, perforin. Results Ⅰ , Ⅱ ,Ⅲ ,Ⅳ stages of NSCLC presented CD8^＋T cell were （54. 14±10.80）%,（43.21±8.57）%, （ 32.17 ± 7.27） %, （ 24.52 ± 5.61 ） %. Interferon -γ in CD8^＋ T cell was （ 69.84 ± 12.34） %, （ 56.27 ± 10.57 ） %, （ 45.15 ± 8.54） %, （38.58 ± 6.89） %, respectively; perforin subgroups in the above four stages were （ 66.24 ± 13.57） %, （55.28± 11.73） %, （43. 87±8.84） %, （36.21 ±5.85） % ,respectively. The difference of interferon-γ, perforin of CD8^＋T cell were significant between two stages in the above four stages （ P〈0.01）. CD8^＋ T cell, interferon -γ, perforin negative correlated with the degrees of NSCLC （ rs=- 0. 824, -0. 764, - 0. 746, respectively）. Conclusion There were lower interferon-γ,perforin of CD8^＋T cell of peripheral vein blood in Ⅲ , Ⅳstage of NSCLC,which was negative significantly correlated to the degree of NSCLC. The cell immune of killing cancer cell had defect in advanced NSCLC.